valuat peg bempeg initi perform
broad pipelin base mainli proprietari pegyl technolog
platform initi coverag perform rate price
target base belief share fairli valu current level repres
reason risk-reward balanc given depend bempeg i-o
combin trial potenti upsid drug candid
success track record develop pegyl drug candid current
market biopharma compani howev think
current major valu driver bempeg appear below-averag probabl
success support opinion wait updat would
advis bempeg clinic outcom may weigh share major overhang
research-bas compani leverag proprietari pegyl
platform discov develop new drug candid number
approv pegyl medicin market partner compani
nktr pipelin consist pegyl drug candid either develop
partner lead biopharma compani
think flagship candid bempeg drive sharehold valu
near medium term import near-term catalyst includ
updat melanoma trial readout
atezolizumab avelumab studi may trigger signific market reaction
alreadi present data bempeg nivo studi includ
melanoma muc show meaning orr seem
margin higher nivo orr singl agent respect indic
howev result confirm random set
certain kol question current bempeg trial
think correl across bempeg studi pipelin rel
high thu leav us alloc rest valuat two drug
candid onzeald onzeald pegyl version
irinotecan success use chemotherapi number cancer
indic mu-opioid develop treat chronic pain
key downsid risk price target includ clinic develop
regulatori risk bempeg addit risk come build commerci
infrastructur associ increas sg expens anticip
competit combin therapi cancer indic upsid risk
includ acquisit signific premium better expect clinic data
bempeg and/or drug pipelin
year price histori
appli
cancer autoimmun diseas
chronic pain oper
unit state europ geograph
compani base san francisco ca
analyst certif import disclosur see disclosur
focus
neutral view base belief share
fairli valu repres reason risk-reward balanc
given compani depend bempeg i-o combin
trial potenti upsid drug candid
success track record develop pegyl drug
candid current market biopharma
bempeg appear below-averag probabl success
support opinion wait updat
would advis bempeg clinic outcom may weigh
share major overhang
activ bempeg combin melanoma rcc
muc demonstr registr studi
statist signific result attain trial onzeald breast
approv launch chronic pain indic
 updat
 updat collabor scope registr trial
 onzeald attain studi readout breast cancer
 fda decis
posit differenti bempeg activ combin
checkpoint inhibitor registr trial
novel bempeg combin cancer indic
greater expect advanc pipelin asset
acquisit signific premium
bempeg activ combin trial checkpoint inhibitor
onzeald clinic trial take longer expect and/or
competit landscap i-o limit bempeg commerci
early-stag pipelin asset fail differenti offer strateg
advantag partnership collabor
price target base dcf valuat methodolog employ wacc termin growth rate
view appropri compani clinic stage asset given access partnership financ biopharma
compani estim bempeg world-wide risk-unadjust sale could reach see onzeald risk un-adjust sale
breast cancer reach risk-unadjust sale reach see royalti mileston
smaller contributor revenu employ risk adjust bempeg indic onzeald breast cancer
chronic pain
key downsid risk price target clinic develop regulatori risk bempeg addit risk includ build
commerci infrastructur target indic higher anticip competit i-o combin upsid risk includ
acquisit signific premium better expect clinic data bempeg drug pipelin
initi coverag nektar perform rate
price target base larg current risk/reward profil two lead drug
candid bempegaldesleukin bempeg onzeald
februari nektar sign collabor agreement bristol-my
squibb led stock appreci reach all-tim high march
sinc march nktr stock lost valu due mainli
delay uncertainti surround bempeg
believ highli depend success bempeg broad
bempeg program current contribut sotp analysi assign
mix po limit clinic data support efficaci
combin trial bempeg i-o agent
combin
believ potenti failur bempeg program may strong neg
effect stock may cast shadow rest program
hand success bempeg trial lead signific share appreci even
upsid acquisit opportun larg pharma
due larg mental account contribut bempeg current stock price
associ risk/reward profil rate stock perform clariti
asset addit clinic data
price target base dcf valuat
methodolog assum wacc residu growth rate
view appropri given histor financ oper mainli
collabor agreement larg biopharma compani plan
launch pipelin asset expect period
end nektar cash market secur
manag guid cash equival end nektar current
market capit around
sotp analysi impli higher valu stock per share mostli driven
bempeg cash balanc howev believ given rel low probabl
success bempeg indic cash balanc would discount
investor bempeg news turn neg
includ nktr early-stag candid valuat analysi re-
assess contribut nktr valuat pipelin advanc
probabl success late-stag drug candid follow
bempeg indic mileston payment associ
bempeg believ high correl across bempeg trial
believ statist signific
data solid address popul approv drug highli
influenc neg opioid sentiment
onzeald think onzeald chemic structur pegyl
irinotecan well prior clinic trial impli clinic meaning pathway
regulatori approv triple-neg breast cancer tnbc
key downsid risk price target includ clinic develop risk bempeg
multipl clinic studi across number cancer indic
onzeald breast cancer patient addit risk come build
commerci infrastructur cancer indic post-regulatori approv
grant less expect sale due higher anticip competit failur
gain support physician commun us payer may requir
signific addit fund pre-launch commerci oper form
key upsid risk price target includ acquisit signific premium
current share price better expect clinic data bempeg onzeald
drug pipelin
upcom catalyst includ updat scope collabor
regard bempeg registr trial addit registr trial combin
checkpoint inhibitor subsequ top-line readout melanoma trial
primari import confirm clinic efficaci bempeg random
catalyst includ updat onzelad attain trial breast cancer
potenti fda advisori committe schedul
exhibit catalyst calendar
histori stock price ownership
nktr stock price ytd vs nbi
ownership mostli invest advis mutual fund manag top
institut investor approxim stock insid own
averag volum share current short interest float
stock price decreas sinc march collabor
anounc
factset oppenheim co note result view indic futur result
nektar research-bas biopharmaceut compani focus
discov develop medicin variou therapeut area includ oncolog
pain manag immunolog
leverag proprietari pegyl platform discov design new drug
candid pegyl process modif biolog molecul coval
conjug polyethylen glycol non-tox non-immunogen polym
use overcom disadvantag associ approv medicin
pegyl chang physic biochem properti molecul
conform electrostat bind hydrophob
better
pharmacokinet qualiti new pegyl drug overal pegyl improv solubl
decreas immunogen increas drug stabil retent time blood
reduc proteolysi qualiti allow reduc dose frequenc so-
nektar number approv pegyl medicin market
market partner compani nktr pipelin also consist pegyl drug
candid either develop partner lead
nektar pegyl approv medicin includ neulasta pegfilgrastim market
cimzia certolizumab pegol market ucb nevertheless spite
acknowledg success commerci drug limit
first-gener pegyl techniqu use biolog exampl
limit includ sub-optim bioavailability/bioact limit abil use
fine-tun properti drug
think three major potenti value-driv therapeut area
develop immuno-oncolog number indic mostli bempeg breast
cancer onzeald pain manag
area i-o nektar develop medicin target biolog pathway
stimul sustain bodi immun respons modul activ key
immun cell cytotox cell nk cell increas number
improv function recogn attack cancer cell
compani advanc drug candid bempeg bempegaldesleukin nktr-
seem pegyl version aldesleukin proleukin initi
approv metastat renal cell carcinoma rcc metastat melanoma
bempeg biolog bias signal one receptor
subunit stimul prolifer growth nk cell tumor
micro-environ assum increas express immun cell
partner bristol-my squibb partner execut clinic
trial pharmacolog agent checkpoint inhibitor may potenti
complementari mechan bempeg major indic pursu includ melanoma
rcc urotheli carcinoma utc
nektar also proprietari non-partn program relat bempeg develop
drug candid i-o portfolio includ
earlier stage develop
onzeald also known etirinotecan pegol next-gener
topoisomeras inhibitor develop treat metastat breast cancer
march nektar announc top-lin data beacon studi onzeald
evalu onzeald single-ag therapi women advanc metastat
breast cancer studi compar onzeald activ control arm compris
singl chemotherapi agent physician choic patient heavili pre-treat
median three prior therapi metastat diseas although top-lin
analysi patient show month improv mo trial
file europ condit approv onzelad howev chmp
adopt neg opinion due statist defici beacon trial
nektar current run anoth studi onzeald name attain breast
cancer patient brain metastas
also known oxycodegol novel mu-opioid analges drug candid
develop chronic pain condit file nda
treatment chronic low back pain opioid-nav adult patient pdufa date
nektar receiv letter fda juli agenc postpon product-
specif advisori committe meet opioid analges includ one previous
schedul agenc continu consid scientif polici issu
relat opioid drug
time file nektar receiv action letter fda regard
nektar nda therebi result fda meet pdufa goal
date august
nektar continu work fda submiss new pdufa date
yet establish estim ad com meet may
happen end year
bempeg
bempeg pathway agonist design provid rapid
activ prolifer cancer-kil effector cell nk cell without
over-activ immun system bempeg stimul cancer-kil immun cell
bodi target receptor found surfac immun
cell also known receptor beta subunit key
signal receptor known increas prolifer effector cell
receptor select intend increas efficaci improv safeti exist
exhibit bempeg descript mechan action
bempeg appear pegyl version aldesleukin market proleukin
initi approv treat metastat rcc melanoma singl
aldesleukin shown cr rate metastat rcc cr rate
metastat melanoma opinion low efficaci number given lack
altern treatment statist signific success cancer
treatment welcom time
hand patient achiev complet respons tend
somewhat durabl month rcc month melanoma
exhibit aldesleukin trial result packag insertrespons data
rcc melanoma studi shown aldesleukin-
moreov life-threaten grade advers event report
exhibit aldesleukin trial result packag inserta data
aldesleukin studi also conclud approv high-dos aldesleukin iu per kg
mg/kg everi hour iu administ daili signific toxic low-dos
aldesleukin clinic effect rcc melanoma low dose
exhibit aldesleukin trial result packag insertlack efficaci dose
nccn guidelin aldesleukin
nccn guidelin cutan melanoma version mention
treatment associ signific risk sever toxic complet respons
rate howev patient demonstr complet respons second
subsequ line treatment long-term overal surviv effect overal due
low respons rate high toxic prefer option consid less
safe effect checkpoint inhibitor braf therapi option
nccn guidelin kidney cancer version mention
treatment therapeut option
nccn guidelin nsclc version bladder version
mention therapeut option conclus studi
support use nsclc bladder cancer awar
bempeg current evalu number registr trial combin
nivolumab includ metastat melanoma metastat rcc metastat
nektar believ base initi data bempeg drive new t-cell clone
exhibit bempeg promot t-cell traffick tumor
melanoma data bempeg nivolumab present show cr
orr
exhibit bempeg nivo data melanoma
nivolumab melanoma approv base trial
show cr orr singl agent recent updat show
nivolumab cr follow-up studi reach singl agent
combin ipilimumab cr number still cr bempeg nivo
muc data bempeg nivolumab show cr orr
exhibit bempeg nivo data muc
nivolumab approv base trial show
cr orr singl agent
nektar manag hypothes bempeg activ respons partial
base mous model conduct anim studi bladder cancer show
better respons bempeg alon
exhibit bempeg nivo data anim model
moreov studi bempeg singl agent patient advanc
pretreat solid tumor show biolog activ bempeg
above-ment studi patient evalu efficaci although
orr observ base recist criteria patient experienc
maximum tumor reduct
howev none studi conduct random set head-to-
head comparison bempeg nivo vs nivo alon rel high orr cr
level shown melanoma uc prove efficaci safeti combo studi
unclear much increment efficaci due addit bempeg
critic bempeg studi
march annualt oppenheim healthcar confer host
keynot speaker dr jason luke medic oncologist univers chicago dr
luke extens oncolog experi clinic investig primari focu
time oppenheim publish note spot red flag drug develop
kol takeaway commentari dr luke regard bempeg nivo
studi open enrol
exhibit bempeg trial design discuss oppenheim healthcar confer
dr luke also appear draw similar epacadostat bempeg
trial trial exhibit red flag outlin dr luke absenc
random data monotherapi minim select patient robust biomark
combo efficaci failur checkpoint inhibitor
exhibit bempeg trial design discuss oppenheim healthcar confer
term collabor
februari nektar enter second agreement pursuant
nektar jointli develop bempeg combin nivolumab
ipilimumab compound parti agre jointli commerci
bempeg world-wide basi april close date transact
paid non-refund without clawback provis per ceo comment
earn call up-front cash payment purchas nktr
stock per share
pursuant agreement nektar also elig payment upon
achiev undisclos develop regulatori mileston total
upon achiev undisclos sale mileston
exhibit agreement detailsup-front futur mileston
nektar record world-wide sale revenu bempeg nektar retain
retain relat net
 expens respons expens relat bempeg
nivo develop wherea respons howev
expens cap per year
exhibit agreement detailsr expenditur
nektar also develop bempeg collabor partner outsid indic
develop
exhibit agreement detailsexclus
novemb enter clinic collabor evalu
sever combin regimen multipl cancer set includ metastat castration-
resist prostat cancer squamou cell carcinoma head neck
combin regimen collabor evalu bempeg avelumab anti-
antibodi develop merck kgaa talazoparib parp inhibitor
develop enzalutamid androgen receptor inhibitor develop
astella pharma
februari start dose-escal studi takeda evalu
bempeg takeda investig medicin dual inhibitor spleen
tyrosin kinas advanc non-hodgkin lymphoma
nektar also work collabor vaccibodi evalu bempeg
vaccibodi person cancer neoantigen vaccin proof-of-concept studi
regard non-bmi clinic collabor bempeg share cost
 expens respect appear
total clinic develop cost alloc bempeg
respect
exhibit spend per molecul
take account cost relat gaap-bas includ personnel
cost sbc appear bempeg-rel cost
guid cost rang
bempeg sale forecast po
believ bempeg risk-unadjust sale reach melanoma
rcc utcth three late-stag indic mention nktr
websit sec file howev assum probabl success
current registr trial mainli enough evid
random set prove superior activ bempeg vs control arm
onzeald previous known etirinotecan pegol next-gener
topoisomeras inhibitor drug candid announc top-lin data
beacon clinic studi onzeald single-ag therapi women
advanc metastat breast cancer beacon studi compar onzeald
activ control arm compris singl chemotherapi agent physician choic
patient heavili pre-treat median three prior therapi
top-lin analysi patient trial onzeald show month
improv median overal surviv month patient receiv
onzeald compar month patient receiv base stratifi
log-rank analysi primari endpoint measur hazard ratio surviv
onzeald group compar activ control arm p-valu
achiev statist signific secondari endpoint beacon studi
includ object respons rate progression-fre surviv achiev
statist signific studi also announc observ signific
overal surviv benefit two pre-specifi subgroupspati histori brain
metastas patient baselin liver metastas studi entri
previou studi irinotecan breast cancer mostli includ non-random
clinic trial unselect previous treat patient respons rate
studi rang
june nektar file ema condit approv onzeald
adult patient advanc breast cancer brain metastas began
enrol patient attain studi compar os patient breast
cancer brain metastas treat onzeald vs juli
inform chmp adopt neg opinion condit approv
studi attain breast cancer patient brain metastas on-going
tnbc preval treatment landscap
breast cancer common non-cutan cancer type world tnbc cancer
express estrogen receptor er progesteron receptor pr epiderm
estim around breast cancer case classifi tnbc
tradit tnbc treat single-ag chemotherapi current nccn
guidelin version suggest treatment variou chemotherapi regimen
includ taxan alkyl capecitabin other recent approv tecentriq
atezolizumab recommend posit tnbc patient appear
less tnbc patient
tecentriq approv base improv tecentriq nab-paclitaxel arm vs
howev os result immatur time approv
exhibit biomark breast cancer
moreov recent present data barcelona show interim result
test patholog respons rate tbnc patient neo-adjuv
set placebo group vs pembro group constitut clinic
abraxan tnbc
abraxan paclitaxel protein-bound particl inject suspens initi
approv treat metastat breast cancer includ tnbc
approv base number clinic trial includ random compar
studi abraxan vs taxol paclitaxel inject respons rate abraxan arm
vs taxol arm
current nccn guidelin breast cancer includ tnbc version recommend
use abraxan combin tecentriq late-stag tnbc patient
irinotecan topoisomeras inhibitor inject initi approv us
treatment metastat carcinoma colon rectum
merrimack pharmaceut receiv approv liposom formul
irinotecan inject brand onivyd treatment metastat carcinoma
due company-specif issu merrimack sold right onivyd
merrimack receiv up-front cash plu potenti regulatory-bas
ipsen report eur sale onivyd sale suggest
nektar etirinotecan pegol long-act topoisomeras inhibitor-polym conjug
engin attach irinotecan molecul via biodegrad cleavabl ester-bas
linker polyethylen glycol polym core
believ liposom formul irinotecan sale irinotecan
liposom formul reason compar proxi pegyl
reformul irinotecan onzeald develop nektar
attain studi etirinotecan pegol vs treatment physician choic patient
metastat breast cancer brain metastas
attain studi built base previou beacon studi os
statist signific miss patient beacon studi
exhibit kaplan-mei plot os beacon trial
primari endpoint attain studi os secondari endpoint includ orr
exhibit overview attain studi
believ onzeald risk-unadjust sale may reach breast
cancer brain metastas indic assum probabl success
appropri risk adjust given irinotecan reformul approv
variou cancer indic serv backbon chemotherapi regimen oncolog
also known oxycodegol orally-avail novel mu-opioid analges
molecul develop long-act analges treat chronic pain
design object address abus liabil seriou central nervou
system side effect associ current opioid therapi
creat use nektar proprietari polym conjug technolog
provid long-act profil slow entri abus deterr
properti inher novel molecular structur reli
formul approach prevent convers abus form opioid
may fda grant track design develop
nektar receiv letter fda juli agenc postpon product-
specif advisori committe meet opioid analges includ one previous
schedul agenc continu consid scientif polici issu
relat opioid drug
uncertainli around nationwid opioid crisi reluct fda
approv anoth opioid molecul assum chanc approv
forecast risk-unadjust sale
royalti collabor revenu
nektar number product candid clinic develop approv
product collabor partner invent drug candid
nektar collabor partner licens proprietari intellectu properti
enabl one drug candid
agreement collabor partner may result up-front payment mileston
payment royalti sale certain case nektar also manufactur suppli
proprietari polym materi partner
nektar receiv cash royalti revenu mostli sale adynov
adynov longer-act blood clot protein hemophilia market
takeda movantik orally-avail peripherally-act mu-opioid antagonist
medic treatment opioid-induc constip oic market
total cash royalti book nektar
exhibit revenu type
nektar receiv mileston payment partner payment
includ payment bempeg respect
exhibit revenu source/agr
exhibit revenu source/agr
nektar also expect receiv first launch bempeg
addit launch well global sale mileston bempeg
believ probabl success bempeg-associ mileston payment
probabl success bempeg indic assum po
nektar number early-stag drug candid pipelin valuat
purpos includ drug candid model
appropri establish either potenti sale probabl success
candid time
howard robin presid chief execut offic
howard robin join januari year
biopharmaceut experi manag clinic develop commerci oper
recent mr robin serv presid ceo clinical-
stage biotechnolog compani pioneer rnai-bas therapi seriou diseas
condit includ age-rel macular degener hep asthma rsv
huntington diseas tenur sirna mr robin re-launch compani
led acquisit merck prior sirna mr robin spent year berlex
positionnamepresid chief execut officerhoward robinchief research develop officerjonathan zalevskychief oper officergil labrucheriechief medic officermari tagliaferri perform
laboratori us subsidiari german schere ag
serv corpor vice-president gener manag divis
respons develop drug betaseron interferon ms
fludara fludarabin phosphat cll gener annual global sale excess
also serv member execut committe prior vice-president
financ busi develop cfo berlex earlier career mr robin
senior associ arthur andersen co mr robin hold account
financ fairleigh dickinson univers nj serv member
board truste
jonathan zalevski appoint chief scientif offic decemb lead
biolog translat research guid strategi nektar discoveri portfolio
role also respons safeti assess clinic nonclin
pharmacolog bioanalytical/bioassay small larg molecul process
develop biolog sinc join juli dr zalevski expertis
immunolog well experi across biolog modal therapeut area
help fuel growth nktr immuno-oncolog immunolog pipelin dr
zalevski led discoveri preclin develop regulatori cell
stimulatori agent develop auto-immun diseas partner co
small molecul tlr agonist develop combin
dr zalevski receiv ph biochemistri tetrad program
univers california san francisco ucsf receiv dual bachelor degre
biochemistri molecular cellular development biolog univers
colorado boulder
gil labrucheri appoint senior vice presid chief offic
june role mr labrucheri overse financ legal procur
logist inform technolog function sinc join nektar
mr labrucheri held sever senior leadership posit increas respons
recent serv senior vice presid gener counsel secretari
nektar mr labrucheri receiv univers california
boalt school law member california law review
order coif receiv univers california davi
mari tagliaferri appoint chief medic offic decemb dr
tagliaferri year experi pharmaceut drug develop
oncolog women health well extens regulatori expertis current
role dr tagliaferri overse clinic develop oper biometr medic
affair function sinc join nektar januari provid
strateg develop leadership nktr immuno-oncolog portfolio includ
bias agonist multipl clinic studi across wide
rang tumor type serv strateg develop leader clinic
collabor nektar bristol-my squibb dr tagliaferri receiv
bachelor scienc degre cornel univers medic degre
univers california san francisco ucsf
expect un-adjust sale reach ww driven primarili
bempeg onzeald assum mix probabl success bempeg
probabl success onzeald assum launch bempeg
launch onzelad
exhibit sale forecast
price target base dcf valuat
methodolog assum wacc residu growth rate due
anticip launch peak sale patent expir
june cash balanc
forecast ww un-adjust sale bempeg indic mainli
driven combin regiment nivolumab melanoma rcc muc
assum probabl success bempeg melanoma rcc
utc well mix potenti mileston payment
onzeald forecast ww un-adjust sale indic
primarili tnbc assum probabl success onzeald
forecast ww un-adjust sale lower back pain
indic assum probabl success
nektar except per share data fy risk-adjust total risk-adjust revenu excl bempeg royalti movantik moventig royalti cimzia bempeg melanoma- melanoma rcc- rcc utc- utc chronic back pain- chronic back pain breast breast cancer revenu probabl revenu mileston total revenu perform
exhibit dcf valuat
exhibit incom statement forecast
exhibit balanc sheet forecast
nektar fy asset cash short-term account receiv incl unbil current asset prepaid total current long-term market properti equip oper leas right-of-us total liabilitiescurr liabil account accru accru clinic trial accru contract manufactur accru interest capit leas current portion- oper leas current defer revenu current current liabilities- total current senior secur note capit leas less current portion- oper leas less current liabil relat sale futur royalti defer revenu less current long-term total total stockhold total liabil nektar
exhibit statement forecast
nektar fy incom adjustmentsnon-cash royalti revenu relat sale futur non-cash interest expens liabil relat sale futur stock-bas depreci non-cash chang oper asset liabilitiesaccount receiv incl unbil asset account accru accru clinic trial expenses- accru interest payable- defer flow purchas matur matur sale purchas properti plant flow payment capit leas obligations- proce share issu equiti compens issuanc common stock net issuanc costs- flow effect net increas decreas equival equival sourc oppenheim co compani report
discount analysi except per-shar data mn except per-shar data revenu chang work work capit valu growth valu oppenheim valu per sharetermin valu growth rate
stock price compani mention report octob
